<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 66 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page65.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=66">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 66 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 66</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=66"><img src="../thumb/66.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.6                                                    2020-04 / 35
       EPIMATE, (Activo) Litha [P/S]  Pts.tak. sod. valproate: Init: 0,2 mg/kg bm/day once dly x 2wks.   EPROLEP, (Unicorn) Brimpharm [P/S]
       Topiramate                    follow.by 0,5 mg/kg/day once a day x2 wks. Thereaft.incr.dos by   Sodium valproate
       Indications: As monother.in new.diagn.epilep./ convers. to mono-  max. 0,5-1 mg/ kg every 1-2 wks.until optim.respons.achiev. Usual   Indications: Gen.epilep.partic.with absence/ myoclon./ ton.-clon./
       ther.in pts.with epilep., adjunct. ther.in adults & childr.over 4 yrs.when   maint. dos: 1-5 mg/kg/day once dly.or in 2 div.dos. Max.dly.dos.of   aton.& mix.patt.seiz., part. epilep.with simple or complex seiz./sec-
       inadeq. contr. by convent.first line anti-epilept.meds.for partial onset   200 mg not to be exceed. Pts.aged 2-6 yrs. may require maint. dos.   ond.gen. seiz & specif.syndr.eg.West & Lennox Gastaut, treatm.&
       seiz.with/without second.gen.seiz., seiz. assoc.with Lennox-Gastaut   at higher end of scale.  prev.of mania assoc.with bipol.disords.
       syndr.& prim. general. tonic-clonic seiz.  Contraindications: Monother.in childr.und.12 yrs. not recomm.,   (S3) CR TABS, 45/2.5/0412, 45/2.5/0093, 0094
       (S3) TABS. 43/2.5/0823, 0824, 0825, 0826  safety in pregn.& lactat.not est., safety & effic.in childr.und.2 yrs.&   721460-001: 200 mg, 100, R294,32
       718855-001: 25 mg, 60, R174,90  pts.over 65 yrs not est., hepat./ren.impairm.  720762-001: 300 mg, 100, R436,70
       718856-001: 50 mg, 60, R318,74  Side effects: Sev.skin rash with irrevers.scarr.& assoc.death incl.tox.  721055-001: 500 mg, 100, R722,80
       718857-001: 100 mg, 60, R490,50  epiderm.necrolys & Stev.-Johns. syndr.esp.in chldr.& pts.on concom.   Dosage: Take with food. Do not crush or chew tabs. Admin.once/
       718858-001: 200 mg, 60, R802,50  valproate, bld.dyscras., CNS effs., aggress., trem., paraesthes., tiredn.,   twice dly. Dly.dos.vary accord. to age & body mass. Optimum dos.
       Dosage: Init.at low dos.titrat.to effect.dos.   vis.disturbs., nystagm., vertigo, GI disturbs.  main.determ.by seiz.control.
       Monother: Discont.grad.at 1/3 of concomit.AED dos. every 2 wks.  Special precautions: Close monit.of hepat./ ren., & clott.paramet.,   Adults:
       recomm.unless safety concerns require abrupt withdr.  consid.withdr.if combinat. of unexplain.rash/fev./flu-like sympts./  Epilepsy: Start 600 mg/day where applic in div. dos.incr.by 200 mg/
       Adults: Init: 25 mg nightly x1 wk.incr.at 1-2 wkly. interv.by in-  drowsin.or worsen.of seiz.contr.dur.1st 8 wks.of treatm. exper., abrupt.  day at 3 day interv.until contr. achiev.gen.betw. 1 000-2 000 mg/day.
       crem.of 25-50 mg/day admin.in 2 div. dos. guid.by clinic.outcome.   withdr.may provoke rebound seiz., grad.withdr., monit.childr.weight   If not stabil. aft.2 wks.may incr.to max.of 2 500 mg/day or one other
       Recomm.init. monother. target dos.is 100 mg/day. Max.recomm.   to maint.therap. dos., eval.all pts. prompt. if rash.occur, adhere to   anti-epilept.add.at low dos.
       dly.dos.500 mg/day.           recomm.dos.esp.if valproate used concom., multiorg. dysfunct.&   Treatm.& prev.of mania assoc.with bipol. disords: Recomm.
       Childr.4 yrs and over: Init.0,5-1 mg/kg nightly x1 wk. incr. at   disseminat.intravasc. coagulat.  init.dos: 1 000 mg/day. Incr.as rapid.as poss.to achiev.low.therapeut.
       1-2 wkly.interv.by increm.of 0,5-1 mg/ kg/ day admin.in 2 div.dos.  Drug interactions: Anti-epilept.agents which induc.hepat.drug   dos.produc. desir.clinic.eff. Adjust accord.to indiv.clinic. respons. Est.
       guid.by clinic.outcome.       metabol.enzymes signific. enhanc. metabol., sod.valproate signific.  prophylact.treatm.indiv.with low. effect. dos.
       Recomm. init.target dos.range is 3-6 mg/kg/day. Dos. of up to 500 mg/  reduc. metabol., being a weak inhibit.of dihydrofol. reductase there   Contraindications: Pre-exist.liv.dis., hepat. dysfunct.hist., urea cycle
       day in recent.diagnos.part. onset seiz.in childr.record.  is a poss.of interfer.with folate metabol.dur.longt.ther.  disords, concurr. MAOI, porphyr., pregn.& lactat.
       Adjunct.ther: Adults: Init:25-50 mg nightly x1 wk. Subseq. at wkly.  Side effects: Sev.liv.damage & pancreatit.(with fatalit.), suicide.
       interv.incr.by 25-50 mg/day admin. in 2 div. dos.guid.by clinic.outcome.   EPITOZ, Zydus [P/S]  ideat.& behav., thrombocytopen., revers.prolong.bleed.time, bone
       Usual tot. dly.dos: 200-400 mg in 2 div.dos. Max.dos: 800 mg/day.  Topiramate  marr.depress., red cell hyperplas., leucopen., isolat.fibrinog.reduct.,
       Childr.4 yrs and over: Recomm.tot.dly.dos: 5-9 mg/kg/day in 2 div.  Indications: Adjunct.ther.for adults & childr.over 4 yrs.when inadeq.  allerg. reacts., angioed., hyperammonaem. encephalopathy in urea
       dos. Init.25 mg or less, based on range of 1-3 mg/kg/day at night x1st   contr.by convent.first line anti-epilept.meds.for partial onset seiz.with/  cycle disords., hyperglycinaem., psych.disords.incl.amnes./sleep
       wk. Incr. dos.at 1 or 2 wk.interv.by increm.of 1-3 mg/kg/day admin.in   without second.gen.seiz., seiz.assoc.with Lennox-Gastaut syndr.&   disords./ somnol./behav.& mood or ment.changes, atax., trem.,
       2 div.dos.guid.by clinic.outcome.  prim.generalis.tonic-clonic seiz.  headache, dizzin., abnorm.gait., cataton. reacts., dysarthr., hyperton.,
       Contraindications: Safety & effic.in childr.und. 4 yrs.not est., safety   (S3) TABS, 41/2.5/0711, 0712, 0713  hypokines., paraesthes., incr.reflex., speech disords., tard. dyskines.,
       in pregn.& lactat.not est.    710899-001: 25 mg, 60, R186,51  extrapyramid.sympts., incr.alertn., amblyop., nystagmus, spots bef.
       Side effects: Vis.disturbs.incl.ac.myopia assoc. with second.clos.  710900-001: 50 mg, 60, R368,21  eyes, diplop., conjunctivit., dry eyes, eye/ear pain, tinnit., otit. me-
       angl.glauc.even in paed.pts., nystagm., diplop., metabol.acidos.,   710901-001: 100 mg, 60, R512,93  dia, deafn., vertigo, palpitat., tachycard., hypo-/hypertens., vasodi-
       memory impairm., bld.dyscras., decr.weight, anorex., psych. dis-  Dosage: Init.at low dos.titrat.to effect.dos. Tabs. not to be broken.  lat., pharyngit., flu syndr., dyspn., pneumon., bronchit., epistax., incr.
       ords.incl.mood disturbs., suicid.ideat. / attempts., CNS effs., par-  Adults: Init: 25-50 mg nightly x1 wk. Subseq.incr. at wkly.interv.by   cough, rhinit., sinusit., GI disturbs., haematemes., periodont. abscess,
       aesthes., speech disord., abnorm. gait., hypoaesthes., oligogidros.,   25-50 mg/day & admin.in 2 div. dos. guid.by clinic.outcome. Effect.  anorex., alopec., hirsutism, acne, skin & subcutan.tiss.disords.incl.
       card. disords., rhinit., pharyngit., pneumon., GI effs., hepatotoxic.,   dos: 200-400 mg dly.in 2 div.dos. Max.dos: 800 mg/day.  Stev.Johns. syndr., back/neck pain, neck rigid., leg cramps, arthralg.,
       hepatit.& hepat.fail. pancreatit., skin disords. incl.Stev.-John.syndr./  Childr.4 yrs and old: Init.25 mg nightly x1st wk. incr. dos.at 1 or 2   arthrosis., myalg., myasth., urin.incont., cystit., revers.defects in ren.
       tox.epiderm. necrolysis/ erythema multiforme, ren.fail., nephrolith-  wk.interv.by increm.of 1-3 mg/ kg/day admin.in 2 div.dos.if more than   tubul.funct., menstr. changes, vag.haemorrh., amenorrh., dysmenorrh.,
       ias., asthen., vir.infect.    25 mg/day. Recomm.dos.thereaft.5-9 mg/kg/day in 2 div.dos. Dos.  metrorrhag., vaginit., gynaecomast., infects., asthen., periph.oed., fev,
       Special precautions: Discont.ther.if syndr.of ac. myopia assoc.with   titrat.guid.by clinic.outcome.  fatig., unus.weight gain/ loss, fev., chest pain, chills, oed., malaise.
       second.clos.angl.glauc.occurs, contracept. effic.poss.decr., eval.ser.  Contra-indications: Safety in pregn.& childr. und. 4 yrs.not est.,   Warnings and special precautions: Pts.at high risk of liv.dys-
       bicarbon.lev. dur. ther.& reduce/discont.if necess., chron. metabol.   unknown if excret.in breast milk.  funct.esp.with multipl.anticonvuls. ther. are infts. & childr.und.3 yrs.
       acidos.reduc.growth rates in paed.pts.& leads to nephrolithias.   Side-effects: Ac.myopia assoc.with second.clos. angl. glauc., fatig.,   with sev.seiz. disords. partic.with brain damage/ment.retard.&./ con-
       incr.fract.risk, incr.adverse effs. with lamotrigine, pts.advis.to report   asthen., injury, vir.infect., CNS disords., paraesthes., speech & relat.  genit. metabol.or degenerat.dis., monit.clinic. sympts.& liv.funct.tests
       chang. bleed. patterns when tak.estrog.-contain. contracept., con-  speech disords., co-ordinat.prob., trem., hyperkines., GI disturbs.,   incl.prothromb.rate dur.1st 6 mnths. for early signs of hepat.fail., dis-
       com.meds.predispos.to nephrolithias. incr.risk of ren.stone format.,   incr.saliva product., pancreatit., psych. disords., psychomot.slow.,
       cross. placent.barrier in animals, outweigh benef.-risk dur. pregn.,   diffic.with memory/ conc./attent., depress., mood prob., personal   cont. concom. salicylates as precaut., hepat.fail.with pancreatit.incr.
       pass.into breastmilk, poss.congenit. malformat. if used dur.pregn.,   changes, anorex., aggress., emot.labilit., insomn., agitat., suicid.  fatal outcome risk, sev.liv.damage and pancreatit.risk decr.with age,
       grad.withdr., monit. recomm. if rapid withdr.requir., ren./hepat.funct.   ideas/attempts, apathy, weight decr., abnorm.vis., nystagm., diplop.,   discont. ther. with pancreatit., monit.for suicid.ideat.& behav., pres.
       impairm., adeq.hydrat.esp.prior/dur exerc.& expos. to warm temp.,   ac.& second. angle closur.glaucom., conjunctivit., tinnit., pharyngit.,   in breast milk, incr.incid.of congenit.abnorm. report.in both untreat.&
       monit./appropr.treatm.in case of suic. ideat., avoid concom.CNS de-  dyspn., rhinit., pneumon., bld.disord., thromboembol.events, purpur.,   treat.epilept., caref. screen.of pregn.by alpha-foetoprot measurem.
       press./alcoh., monit. phenytoin /digoxin/Li lev., diab.contr.monit. with   dysur., urin.freq., incontin., haematur., ren.calcul., nephrolithias., ren.  & ultrasound & amniocentes.if indic., elderly, ren. insuffic., bld.tests
       concom.metformin./pioglitazone, remov.from plasma by haemodialys.  fail., hepat.fail., hepatit., gingivit., incr.sweat., skin & mucosal reacts.  recomm.in spontan. bruis./ bleed.& bef.surg., eval.risk vs.benef.in
       Interactions: Poss.incr.phenytoin plasma conc., phenytoin & car-  incl.erythema multiforme/ pemphigus/Stev.-John.syndr.& tox.epi-  SLE, false posit.in urin.test.of poss.diabet., suspect.urea cycl.en-
       bamazepine decr.plasma conc., decr. ser.digox., plasma clear.of OC’s   derm. necrolysis, hypotens.  zym.defic., dent.proced., sched.surg., warn pts of poss.weight gain
       oestrog. compon. incr.signif., hydrochlorothiazide incr.Cmax & AUC, incr.  Special precautions: Discont.ther.if syndr.of ac. myopia assoc.  Drug interactions: Effs.of other psychotrop. potent., rais.phenobarb.
       Cmax & AUC of metformin, AUC & C max incr. of nortriptyline metabol.,   with second.clos.angl.glauc.occurs, withdr.grad., ren./hepat.impairm,   plasma conc., primidone plasma lev.incr., phenytoin tot.plasma conc.
       incr.C max & AUC with propranolol.  avoid concom. meds.predispos.to nephrolithias., adeq.hydrat.esp.   decr.& phenytoin free form incr., tox.eff.of carbamazep. potent., me-
                                     prior/dur exerc. & expos.to warm temp., potent. teratogenic.risk,   tabol.of lamotrig.reduc., zidovud. plasma conc.rais., anti-epilept.eff.
       EPITEC, Cipla Medpro [P/S]    contracept.effic.of OC’s poss. comprom., OC’s to contain at least 50   antagon.by antidepress. & neurolept.which low.seiz.threshold, ser.
       Lamotrigine.                  µg of oestrog./ use alt.non-hormon.contracept., hypospad. report.  conc.decr.by anti-epilept.with enzyme induc. eff., incr.ser.conc.with
       Indications: Adults & childr.over 12 yrs: Monother./add-on   in male babies expos.in utero, remov.from plasma by haemodialys.  felbamate, mefloquine incr. valproic acid metabol.& has convuls.
       treatm.of part.epilepsy with/ without second.general.ton.clon.seiz.,   Drug interactions: Poss.incr.phenytoin plasma conc., phenytoin   eff., chloroquine may low.seiz.threshold, valproate free ser.lev.incr.
       & in prim. gen. tonic-clon.seiz. Childr. 2-12 yrs: Add-on treatm. of   & carbamazepine decr.plasma conc., decr.serum digox.lev., plasma   by high.prot.bound agents (aspirin), anticoag.eff.of vit.K depend.fact.
       part.epilep.with/without second gen. tonic-clonic seiz.not satisfact.  clear.of OC’s oestrog.compon incr.signific.  anticoags.incr., cimetid.& erythromyc.poss.incr.ser.lev., valproate bld.
       control.with other anti-epilept.meds., add-on treatm.of seiz.assoc.   lev.decr.by carbapenem antibiot.
       with Lennox- Gastaut Syndr.   EPLEPTIN, Ranbaxy [P/S]
       (S3) TABS, A38/2.5/0571, 0572, 0573, 0574  Gabapentin.     FYCOMPA, Equity &
       704379-001: 25 mg, 60, R105,54  Indications: Adjunct.to other std.anticonvuls. meds. where adeq.  Perampanel
       704380-001: 50 mg, 60, R152,40  seiz.contr.has not been achiev. with agents use.alone/in combinat.,   Indications: Adjunct.ther.in partial onset seiz. with/without second.
       704381-001: 100 mg, 60, R252,12  simple & complex part.seiz.with/without second.gen.tonic-clonic seiz.  generalisat.in pts ≥ 12 yrs with epilep.
       704382-001: 200 mg, 60, R405,60  (S3) CAPS, A40/2.5/0158, 0159, 0160  (S5) TABS, 47/2.5/1196, 1197, 1198, 1199, 1200, 1201
       Dosage: Do not exceed max.recomm.dos.esp.in combinat.with   707622-001: 100 mg, 100, R184,05  723048-001: 2 mg, 7, R463,62
       valproate. If calcul.dos.,esp.in childr. does not equate to whole tab.  707623-001: 300 mg, 100, R459,49  723049-001: 4 mg, 28, R1 854,66
       admin.dos. as equal to low.no.of whole tabs.  707624-001: 400 mg, 100, R459,49  723050-001: 6 mg, 28, R1 854,66
       Monotherapy: Adults & childr.over 12 yrs: Init. 25 mg once dly.  Dosage: Phenobarbit./phenytoin/valproic acid & carbamazepine   723024-001: 8 mg, 28, R1 854,66
       x2 wks., follow.by 50 mg once dly. x2 wks. Thereaft.dos.should be   poss.as adjunct.without alt.plasma or serum conc.of either agent. If   723051-001: 10 mg, 28, R1 854,66
       incr.by max.50-100 mg every 1-2 wks.until optim. respons. achiev.   discont/add.an alt. med.do so grad.over a minim.of 1 wk.  723052-001: 12 mg, 28, R1 854,66
       Usual.maint.dose: 100-200 mg / day admin.once dly or in 2 div.dos.  Adults & childr.over 12 yrs: Init.300 mg 3xdly. incr.grad.accord.to   Dosage: Adults & adolesc: Init.: 2 mg dly.at bedt. Adjust.in increm.
       Add-on therapy: Adults & childr.over 12 yrs. Pts.not tak.sod.   response. 900-1 800 mg/day in 3 div. dos.with interv.of not more than   of 2 mg at interv.of at least 2 wks accord.to tol.& respon. Maint: 4-8
       valproate: Init: 50 mg once dly x2 wks.follow.by 100 mg/day in 2   12 hrs. effect. for most pts. Dos.up to 3 600 mg in div.dos. 3x dly.for   mg/day taken at night. Max: 12 mg/day. Pts.tak.concom. meds.
       div.dos.x2 wks. thereaft.dos. should be incr.by max. 100 mg every 1-2   short period have been tol.  that short. t½ of perampanel: Titrate at interv.of at least 1 wk.
       wks.until optim.respons.achiev. Usual. maint. dos.to achieve optim.  Contraindications: Safety & effic.in childr.und. 12 yrs., pregn.&   Miss.dos: Sngl.miss.dos: Take next dos.as sched. More than 1
       respons: 200-400 mg /day in 2 div. dos.  lactat.not est.   dos.miss.for contin period. &lt;5 half-lives: Consid.re-start.treatm.
       Pts.tak.sod. valproate: Init: 25 mg every altern. day x2 wks., follow   Side effects: CNS eff.incl.atax., trem.& vertigo, headache,   from last dos. lev. Discont.for period.&gt;5 half-lives: Foll.init. dos.
       by 25 mg once dly.x2 wks. thereaft.dly.dos.should be incr.by max. 25-  dysarthr.,amnes., twitch., abnorm.co-ordinat., paraesthes., GI dis-  recommendat.
       50 mg every 1-2 wks.until optim.respons. achiev. Usual maint.dos.to   turbs., dent.abnorm., diplop., amblyop., nystagm., rhinit., URTI effs.,   Side effects: V.common: Dizzin., somnol. Common: Decr./incr.ap-
       achieve optim.respons: 100-200 mg/ day giv.once a day/in 2 div. dos.   skin rash, prurit., abras., acne, psych.disords., impot., myalg., back   pet., aggress., anger, anx., confus.state., atax., dysarthr., bal.disord.,
       Do not exceed tot.dly.dos.of 200 mg.  pain, fract., periph.oed., vasodilat., bld.dyscras., vir. infect., incr.ap-  irritabil., vertigo, back pain, naus., diplop., blurr.vis., gait disturb., fatig.,
       Childr. 2-12 yrs: Pts.not tak.sod.valproate: Init.2 mg/kg bm/day   pet.result.weight gain., fev.  incr.weight, fall. Uncommon: Suicid. ideat./attempt. Post market:
       in 2 div.dos.x2 wks., follow.by 5 mg/kg/day x2 wks. Thereaft.the dos.  Special precautions: Hist.psychot.illn., poss. status epilept.with   Skin reacts., ac. psychos., hallucinat., delus., paranoia, delir., disori-
       should be incr.by a max. 2-3 mg/kg every 1-2 wks.until optim. respons.  abrupt withdraw., elderly, imp.ren.funct., grad.reduc./discont.  entat., imp.memory
       achiev. Usual maint. dos.to achieve optim.respons: 5-15 mg/kg/day   Drug interactions: Mg & Al contain.antacids reduc.bioavail., CNS   Warnings and special precautions: Suic.ideat. /behav., eval.
       in 2 div.dos. Max. dly.dos.of 400 mg not to be exceed.  depress.effs.incr.by CNS depress.  poss.S/E on ability to drive/use machines, may decr. effectiven.of</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page65.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>&nbsp;&nbsp;&nbsp;<a href="page64.html">64</a>&nbsp;&nbsp;&nbsp;<a href="page65.html">65</a>&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>&nbsp;&nbsp;&nbsp;<a href="page69.html">69</a>&nbsp;&nbsp;&nbsp;<a href="page70.html">70</a>&nbsp;&nbsp;&nbsp;<a href="page71.html">71</a>
             </td>
             <td width="35%"><a href="page67.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page67.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
